anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A total of 12 studies were performed with epidural administration of NAROPIN for cesarean section. Eight of these studies involved 218 patients using the concentration of 5 mg/mL (0.5%) in doses up to 150 mg. Median onset measured at T6 ranged from 11 to 26 minutes. Median duration of sensory block at T6 ranged from 1.7 to 3.2 h, and duration of motor block ranged from 1.4 to 2.9 h. NAROPIN provided adequate muscle relaxation for surgery in all cases. 

In addition, 4 active controlled studies for cesarean section were performed in 264 patients at a concentration of 7.5 mg/mL (0.75%) in doses up to 187.5 mg. Median onset measured at T6 ranged from 4 to 15 minutes. Seventy-seven to 96% of NAROPIN-exposed patients reported no pain at delivery. Some patients received other anesthetic, analgesic, or sedative modalities during the course of the operative procedure.
Background: Today, colonoscopy is widely used in many diseases, especially in the screening and diagnosis of colorectal cancers. Colonoscopy is considered a procedure that disturbs the patient's comfort because it is a very invasive and painful procedure. Along with physical discomfort during the procedure, it triggers emotional disturbances such as fear, and anxiety in the patient.

Purpose: To examine the effect of virtual rain forest and glass waterfall on satisfaction, comfort, anxiety, and vital signs before colonoscopy Method: The population of the study consists of all patients who will apply to Mardin Education and Research Hospital, Department of General Surgery, Endoscopy Unit and will be scheduled for colonoscopy. The sample will be represented by 135 patients whose colonoscopy procedure is planned between the specified dates and who meet the criteria for inclusion in the sample. In calculating the sample of the study, power analysis will be performed and it will be found the effect size of 0.40, 95% power and 0.01% margin of error for this study, that a total of 135 individuals for the three groups and at 60 individuals for each group. G\*Power, version 3.0.10 was used for statistical power analysis. The study group of 93 people to participate in the study will be divided into three equal groups in accordance with the random numbers table obtained the computer- based Research Randomizer program. Before the arthroscopy procedure, the patients included in the study will be randomly divided into three groups: 45 rain forest video VR group, 45 glass waterfall group and 45 control group. All participants in the study will first fill out a patient identification form containing patient demographic information. Before the colonoscopy procedure, 360-degree VR rain forest video scenes will be watched 30 minutes using VR head device in virtual glasses group. Glass Water group, patients will watch and listen 30 minutes a portative glass waterfall
PURPOSE: Blood culture (BC) is the standard for diagnosing bloodstream infections. Available blood culture (BC) systems have been developed to shorten the time to detection (TTD) of positive BCs. This study aimed to evaluate the performance of the Mindray TDR automatic BC system by comparing it with the BacT/ALERT®3D system.
METHODS: Sixteen reference strains and 14 clinical isolates were used. Serial dilutions were prepared from all bacterial and yeast colonies with a final concentration of 100 CFU/ml and 10 CFU/ml. The prepared solutions were simultaneously inoculated into the bottles of both systems and placed in blood culture devices.
RESULTS: Three hundred and fifty-two (176 BacT/ALERT®3D and 176 Mindray TDR-X060) blood culture bottles were evaluated, 336 aerobic and 16 anaerobic. At both 10 CFU/ml and 100 CFU/ml dilution, there was no significant difference between the two systems in terms of mean detection times for all isolates (p = 0.965, p = 0.245). When evaluated according to the type of organism, the detection time of gram-positive bacteria at 10 CFU/ml dilution was significantly shorter in the BacT/ALERT system (p = 0.019), whereas detection time for yeasts was significantly shorter with the Mindray system (p = 0.047). The number of anaerobic bacteria was too small to draw statistical conclusions, but we observed a trend of shorter detection times in the Mindray TDR-X060 system.
CONCLUSION: Two systems with similar operating principles showed different concentrations-dependent performances in terms of positivity detection times depending on the type of microorganism. Mindray TDR-X060 system has been found to be safe to use at high concentrations with this at lower concentrations further comparative studies are needed on the newly introduced Mindray system.
[Problem] In the past, it was difficult to suppress damage to natural nails and inflammation of the skin of fingers when softening and peeling off coating films with solvents such as ethanol or acetone in order to remove the cured coating films of photocurable compositions for nails or artificial nails. [Solution] Provided is a photocurable composition for nails, which contains components (A) to (D). Component (A): a urethane-modified oligomer which has a weight average molecular weight of 25,000-100,000 and has two or more (meth)acryloyl groups per molecule. Component (B): a monomer which has two or more ether groups and one (meth)acryloyl group in the molecule. Component (C) (which excludes component (A)): a monomer of a component (c-1) and/or a component (c-2) (component (c-1) is a chain-like monomer having four or more (meth)acryloyl groups per molecule and component (c-2) is a monomer having two or more (meth)acryloyl groups and a cyclic structure per molecule). Component (D): a photoinitiator.
Microplastics (MPs) are ubiquitous environmental contaminants that have negative impacts on health and safety. The gut microbiota plays multiple roles as a newly discovered virtual metabolic organ. The objective of this study was to investigate the potential of MPs to cause liver injury by disrupting the balance of gut microbiota. The results indicated that exposure to MPs resulted in liver damage and disrupted the homeostasis of gut microbiota. MPs significantly reduced the liver organ coefficient, leading to liver cell injury and impaired function. Additionally, there was an increase in the expression of fibril-related proteins, which positively correlated with MPs concentration. Furthermore, MPs increased the relative abundances of Desulfovibrio, Clostridia, Enterorhabdus, Bacteroides, and Gemella while decreasing the abundance of Dubosoella. Different concentrations of MPs exhibited varying effects on specific bacterial groups, however, both concentrations resulted in an increase in pathogenic bacteria and a decrease in beneficial bacteria, as well as alterations in microbial structure. Moreover, MPs induced oxidative stress, inflammation, apoptosis and necrosis in liver cells. The study found that MPs disrupted gut microbiota homeostasis and activated TLR2/NF-κB/NLRP3 pathway in the liver, providing a new insight into the mechanism underlying MPs-induced liver injury. These findings serve as a warning regarding environmental pollution caused by MPs.
The present invention relates to a novel Bifidobacterium breve IDCC 4401 strain (Accession No: KCTC13169BP), which has excellent acid resistance and bile resistance and has a preventive or therapeutic effect on dyslipidemia, and to a dead cell, ID-BBR4401, thereof. A novel strain Bifidobacterium breve IDCC 4401 (Accession No: KCTC13169BP) of the present invention not only has an excellent effect of reducing cholesterol in vivo, but also has a very high level of acid resistance and bile resistance unlike previously known B. breve. Thus, in the digestive tract of animals (especially, humans), the functionality of the strain is shown well and a growth ability is excellent. Accordingly, a continuous and effective in vivo cholesterol-reducing function can be provided. In addition, a dead cell (ID-BBR4401) produced by heat treatment on the strain has an excellent cholesterol-binding ability at the same level as or higher than that of live cells, and also possesses a high level of a binding ability with bile acids, thereby showing remarkable efficacy in excreting bile acids from an animal body. Therefore, ID-BBR4401 of the present invention is very effective in reducing body cholesterol, especially LDL-cholesterol. Also, since an effect of reducing triglycerides in an animal body is remarkable, excellent efficacy is shown in prevention and treatment of dyslipidemia.
A group of 30 AMD patients with typical lesions (drusen and/or retinal pigment epithelial defects) and relatively preserved central retinal function and visual acuity will be enrolled. AMD patients will be randomly divided into two groups: 1. placebo group \[n = 15), taking for three months an oral placebo; 2. Saffron group (n = 15), taking Saffron oral treatment (20 mg/day) for three months. After three months of placebo or Saffron supplementation, patients will be tested with standard ophthalmic examination and FERGs. Then, placebo with Saffron and vice-versa will be changed to the same patients in a cross-over design. After a further three month period of placebo or study drug supplementation, patients will undergo again a standard ophthalmic examination, and FERG. Throughout the study, both patients and experimenters will be masked as to the identity of pills (i.e. whether placebo or study drug), whose identification key number will be kept in a sealed envelope that will be opened only at the completion of the study. Therapeutic compliance will be tested by careful questioning, either at two weeks of treatment (by telephone interview) or at the end of the treatment period, as well as by pill count. Main outcome measures of the study will be FERG amplitude and phase.
Disclosed are a multi-drug combined rehabilitation electuary for type 2 diabetes and the use thereof. The electuary is prepared by compounding the following components, in percentages by weight: 45% to 90% of sorbitol, 5% to 50% of betaine or betaine hydrochloride, and 0.01% to 10% of Span 60. The sorbitol of the present invention enables the dissolved fat to form a stable emulsion or ultramicroemulsion, and has a molecular structure similar to that of a glucose molecule, can simulate the glucose molecule to play a targeted localization role, and also has a certain sweetness to improve the taste of the electuary. The betaine/betaine hydrochloride is a biosurfactant for helping to dissolve fat, and also has the function of protecting and nourishing the liver, and improves the insulin utilization efficiency. The Span 60 enables the fat on the surface of a deposition channel to dissolve gradually. The electuary of the present invention enables the fat deposited on the surface of the channel and the semipermeable membrane to form a stable "oil-in-water" emulsion or ultramicroemulsion, so that the deposited fat is excreted from the body via the excretory system after dissolution and the insulin utilization efficiency is improved.
A cosmetic cleanser containing (i) 0.1-20% wt, preferably 1-15%, of a water-insoluble abrasive component of natural origin, (ii) 1-50% wt, preferably 2-20%, of a biosurfactant and (iii) 0.2-3% wt, preferably 0.3-1.5%, of a thickening agent of natural origin. The abrasive particles may be polylactic acid, sand, silicon dioxide, titanium dioxide, jojoba wax beads, crystalline cellulose and/or comminuted plant parts, e.g. crushed fruit stones or pulverised algae. The biosurfactant may be a glycolipid preferably selected from rhamnolipids, sophorolipids or mannosylerythritol lipids a lipopeptide preferably selected from surfactins, fatty acyl glutamates or fatty acyl glycinates or a combination thereof. A sophorolipid in the form of a mixture of 20-60% acid and 40-80% lactone, or a mono- / dirhamnolipid mixture derived from 3-hydroxydodecanoic acid and 3-hydroxyundecanoic acid are particularly preferred. The thickener may be xanthan gum, guar gum, gellan gum, pectin and/or hydroxymethyl cellulose. The cosmetic cleanser is preferably formulated as a facial or body cleanser and may further contain a non-ionic surfactant of natural origin, such as an alkyl polyglycoside (e.g. coco-glucoside, lauryl glucoside) and/or a fatty acyl glucamide (e.g. lauroyl methyl glucamide). Preferably it contains less than 0.5% wt or is even free of anionic, amphoteric / zwitterionic and cationic surfactants.
Recombinant nodavirus related compositions are disclosed. These compositions include chimeric proteins in which a nodavirus capsid protein is present together with a heterologous peptide segment. The heterologous peptide includes at least one cell-specific targeting sequence, such as a B cell epitope, a T cell epitope, or a sequence specific for another cell type, such as a hepatocyte. The chimeric proteins can be assembled to form chimeric virus-like particles. The chimeric virus-like particles are useful in therapeutic applications, such as vaccines and gene-delivery vectors, and in diagnostic applications, such as kits for the testing of body tissue or fluid samples. Methods for the use of recombinant nodavirus related compositions in therapeutic and diagnostic applications are also described.
Hypoglycaemia is one of the most common causes of convulsions in neonatal period. Repeated hypoglycaemic convulsions have to be addressed with utmost urgency to prevent its morbid sequelae. Repeated ketotic hypoglycaemia in the infantile period needs detailed endocrine evaluation. Our patient is a boy in the third year of his life, had presented in infancy with hypoglycaemic convulsions and hyperpigmentation of skin and mucous membrane. Investigations revealed ketotic hypoglycaemia, hypocortisolaemia with high adrenocorticotropic hormone (ACTH) and normal aldosterone, 17-hydroxyprogesterone (17-OHP) and testosterone levels. This suggested isolated glucocorticoid deficiency without mineralocorticoid deficiency. He responded well to hydrocortisone therapy with resolution of symptoms and normalisation of lab parameters. Genetic study confirmed the diagnosis of familial glucocorticoid deficiency (FGD) with homozygous mutation in NNT (nicotinamide nucleotide transhydrogenase) gene with a novel p.Thr578lle variant. This is the first case of FGD with NNT mutation to be reported from the Indian subcontinent.
The present invention relates to a Chinese traditional patent medicine for treating amenorrhea-galactorrhea syndrome, which takes more than 10 Chinese herbal medicines of crude fossilizid, raw oyster, stir-fried gardenia, turmeric root-tuber etc. as the raw materials. The present invention has the effects of soothing liver, regulating qi, regulating menstruation and generating milk. Based on the differential treatment of the traditional Chinese medicine, the invention is developed by combining the latest scientific research results with the traditional Chinese medicine. The present invention aims at providing the Chinese traditional patent medicine for treating amenorrhea-galactorrhea syndrome. The present invention is characterized by accurate efficacy, safety, convenience, no toxicity or side effects and low price.
All the participants underwent a neurocognitive-rehabilitative training consisting of 24 sessions of BTsN. Each treatment session lasted 45 minutes, and was repeated three times a week for 8 weeks. in the BTsN device used in the S-IVTS group the projector is located behind the patient, thus the shadow of the patient is projected on the screen.
The control group will be receiving usual care at discharge. These participants will not be receiving the BMT4me 2.0 app.
Clinical studies of hydrocodone bitartrate and acetaminophen did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

Hydrocodone and the major metabolites of acetaminophen are known to be substantially excreted by the kidney. Thus the risk of toxic reactions may be greater in patients with impaired renal function due to the accumulation of the parent compound and/or metabolites in the plasma. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

Hydrocodone may cause confusion and over-sedation in the elderly; elderly patients generally should be started on low doses of hydrocodone bitartrate and acetaminophen tablets and observed closely.
OBJECTIVE: To evaluate the effectiveness of neurophysiological pain education in patients with symptomatic knee osteoarthritis considering pain-related variables.
METHODS: A systematic review and meta-analysis was carried out according to the PRISMA guidelines. A search was conducted in PubMed, PEDro Database, Cochrane Library, Scopus, and Web of Science. Only randomized controlled trials enrolling patients ≥ 18 years of age with symptomatic knee osteoarthritis were included. The Downs and Black quality assessment tool was used to assess the quality of the articles, and the risk of bias was evaluated with the Cochrane Risk of Bias Assessment Tool.
RESULTS: A total of 7 studies were included in the study. Most of the studies were rated as "fair" on the Downs and Black quality assessment tool, and in the category of "some concerns" according to the Cochrane Risk of Bias Assessment Tool. Neurophysiological pain education was conducted alone or combined with exercise, joint mobilizations, or self-management programs. The number of sessions ranged from 1 to 10. The meta-analysis results showed significant differences in favor of the intervention group in pain (MD = -0.49; 95% CI = -0.66; -0.32; p < 0.001) and catastrophization (MD = -1.81; 95% CI = -3.31, -0.3; p = 0.02).
CONCLUSION, PRACTICE IMPLICATIONS: Neurophysiological pain education interventions in isolation or combined with exercise, joint mobilizations, or self-management programs have proven to significantly improve pain and catastrophization in patients with symptomatic knee osteoarthritis. These findings could provide clinicians with more information regarding the management of patients with symptomatic knee osteoarthritis.
This study culturally adapts existing evidence-based decision support navigation intervention and tests its efficacy among 200 Chinese and Korean American men and 200 Chinese and Korean American women aged 50 to 75 eligible for colorectal cancer screening. Participants are recruited from primary care physician clinics. The study is designed to compare colorectal cancer screening outcomes between the decision support navigation intervention and the advanced control. Those randomized to the advanced control group only receives an informational booklet, a stool blood test kit and a reminder by mail. Those randomized to the decision support navigation intervention group receives everything the advanced control group receives as well as decision support and navigation contacts. Investigators in the study develop an individualized screening plan using a theory-based online Decision Counseling Program, share the plan with the participants' primary care physicians, and have primary care physicians to encourage the colorectal cancer screening to participants. Using outcomes data collected by survey and medical record review, this study: (1) determines overall colorectal cancer screening adherence in the culturally adapted decision support navigation intervention vs. the advanced control; (2) measures change in colorectal cancer screening decision stage in the culturally adapted decision support navigation intervention vs. the advanced control; and (3) assesses colorectal cancer screening test-specific (stool blood test vs. colonoscopy) adherence in the culturally adapted decision support navigation intervention vs. the advanced control. Additionally, investigators in the study evaluate intervention reach, effectiveness, adoption, implementation, and maintenance using interview data.
Severe diarrhea and sequelae, such as dehydration, hypotension, and renal failure occurred during treatment with NERLYNX. Diarrhea was reported in 95% of NERLYNX-treated patients in ExteNET, a randomized placebo-controlled trial in the extended adjuvant setting who were not required to receive antidiarrheal prophylaxis. In the NERLYNX arm, Grade 3 diarrhea occurred in 40% and Grade 4 diarrhea occurred in 0.1% of patients. The majority of patients (93%) had diarrhea in the first month of treatment, the median time to first onset of Grade ≥3 diarrhea was 8 days (range, 1–350), and the median cumulative duration of Grade ≥3 diarrhea was 5 days (range, 1–139) [see Adverse Reactions ( 6.1)] . 

Diarrhea was reported in 83% of NERLYNX plus capecitabine treated patients in NALA, a randomized placebo-controlled trial in the metastatic breast cancer setting who were required to receive anti-diarrheal prophylaxis in the first 21-day cycle. The majority of patients (70%) had diarrhea in the first 21 days of treatment, the median time to first onset of Grade ≥3 diarrhea was 11 days (range, 2–728) and the median cumulative duration of Grade ≥3 diarrhea was 3 days (range, 1–21). In the NERLYNX plus capecitabine arm, Grade 3 diarrhea occurred in 24% of patients [see Adverse Reactions ( 6.1)] . 

Antidiarrheal prophylaxis has been shown to lower the incidence and severity of diarrhea. Instruct patients to initiate antidiarrheal prophylaxis with loperamide along with the first dose of NERLYNX and continue during the first 56 days of treatment; after day 56, titrate dose to achieve 1–2 bowel movements per day and not to exceed 16 mg loperamide per day [see Dosage and Administration (2.1)]. Consider adding other agents to loperamide as clinically indicated [see Adverse Reactions ( 6.1)] . 

Alternatively, a 2-week NERLYNX dose escalation approach prior to initiation of the recommended treatment regimen with NERLYNX can also be considered for diarrhea management [see Dosage and Administration ( 2.2)]. For patients who used NERLYNX dose escalation, the median time to first onset of Grade ≥3 diarrhea was 45 days (range, 15–132) and the median cumulative duration of Grade ≥3 diarrhea was 2.5 days (range, 1–6). Grade 3 diarrhea occurred in 13% of patients who used NERLYNX dose escalation [see Adverse Reactions ( 6.1)]. 

Monitor patients for diarrhea and treat with additional antidiarrheals as needed. When severe diarrhea with dehydration occurs, administer fluid and electrolytes as needed, interrupt NERLYNX, and reduce subsequent doses [see Dosage and Administration (2.3)]. Perform stool cultures as clinically indicated to exclude infectious causes of Grade 3 or 4 diarrhea or diarrhea of any grade with complicating features (dehydration, fever, neutropenia).